Inhibitors of the arachidonic acid cascade: Interfering with multiple pathways

Basic and Clinical Pharmacology and Toxicology

Volumn 114, Issue 1, 2014, Pages 83-91

  Meirer, Karin ^a   Steinhilber, Dieter ^a   Proschak, Ewgenij ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN INHIBITOR; ARACHIDONIC ACID DERIVATIVE; ARACHIDONIC ACID INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME P450; EPOXIDE HYDROLASE; LICOFELONE; LIPOXYGENASE; NATURAL PRODUCT; PROSTAGLANDIN SYNTHASE; UNCLASSIFIED DRUG;

ARTICLE; DRUG APPROVAL; DRUG DEVELOPMENT; ENZYME INHIBITION; PRIORITY JOURNAL; PROTEIN TARGETING;

ANTI-INFLAMMATORY AGENTS; ARACHIDONATE 5-LIPOXYGENASE; ARACHIDONIC ACID; CYCLOOXYGENASE 2 INHIBITORS; CYTOCHROME P-450 ENZYME SYSTEM; EPOXIDE HYDROLASES; HUMANS; INFLAMMATION; LIPOXYGENASE INHIBITORS; PAIN; PYRROLES;

EID: 84890806672     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12134     Document Type: Article

References (83)

1. Dennis EA, Cao J, Hsu Y-H, Magrioti V, Kokotos G. Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. Chem Rev 2011;111:6130-85.
2. Stables MJ, Gilroy DW. Old and new generation lipid mediators in acute inflammation and resolution. Prog Lipid Res 2011;50:35-51.
3. Piper P, Vane J. The release of prostaglandins from lung and other tissues. Ann N Y Acad Sci 1971;180:363-85.
4. Samuelsson B, Dahlén SE, Lindgren JA, Rouzer CA, Serhan CN. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 1987;237:1171-6.
5. Serhan CN, Hamberg M, Samuelsson B. Trihydroxytetraenes: a novel series of compounds formed from arachidonic acid in human leukocytes. Biochem Biophys Res Commun 1984;118:943-9.
6. Capdevila JH, Falck JR, Dishman E, Karara A. Cytochrome P-450 arachidonate oxygenase. Methods Enzymol 1990;187:385-94.
7. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001;294:1871-5.
8. Chandrasekharan NV, Simmons DL. The cyclooxygenases. Genome Biol 2004;5:241.
9. Kulmacz RJ. Cellular regulation of prostaglandin H synthase catalysis. FEBS Lett 1998;430:154-7.
10. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000;69:145-82.
11. Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Isakson P. Distribution of COX-1 and COX-2 in normal and inflamed tissues. Adv Exp Med Biol 1997;400A:167-70.
12. Fu J-Y, Masferrer JL, Seibert K, Raz A, Needleman P. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 1990;265:16737-40.
13. Smith WL, Urade Y, Jakobsson P-J. Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis. Chem Rev 2011;111:5821-65.
14. Jakobsson PJ, Thorén S, Morgenstern R, Samuelsson B. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci USA 1999;96:7220-5.
15. Woodward DF, Jones RL, Narumiya S. International Union of Basic and Clinical Pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress. Pharmacol Rev 2011;63:471-538.
16. Hirata T, Narumiya S. Prostanoid receptors. Chem Rev 2011;111:6209-30.
17. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888-99.
18. Moncada S, Vane JR. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev 1978;30:293-331.
19. Orehek J, Douglas JS, Lewis AJ, Bouhuys A. Prostaglandin regulation of airway smooth muscle tone. Nat New Biol 1973;245:84-5.
20. Hwang SH, Wecksler AT, Wagner K, Hammock BD. Rationally designed multitarget agents against inflammation and pain. Curr Med Chem 2013;20:1783-99.
21. Yang K, Ma W, Liang H, Ouyang Q, Tang C, Lai L. Dynamic simulations on the arachidonic acid metabolic network. PLoS Comput Biol 2007;3:e55.
22. Singh D. Merck withdraws arthritis drug worldwide. BMJ 2004;329:816.
23. Friesen RW, Mancini JA. Microsomal prostaglandin E2 synthase-1 (mPGES-1): a novel anti-inflammatory therapeutic target. J Med Chem 2008;51:4059-67.
24. Serhan CN, Hamberg M, Samuelsson B. Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc Natl Acad Sci USA 1984;81:5335-9.
25. Haeggström JZ, Funk CD. Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease. Chem Rev 2011;111:5866-98.
26. Rådmark O, Werz O, Steinhilber D, Samuelsson B. 5-Lipoxygenase: regulation of expression and enzyme activity. Trends Biochem Sci 2007;32:332-41.
27. Rouzer CA, Matsumoto T, Samuelsson B. Single protein from human leukocytes possesses 5-lipoxygenase and leukotriene A4 synthase activities. Proc Natl Acad Sci USA 1986;83:857-61.
28. Radmark O, Serhan C, Hamberg M, Lundberg U, Ennis MD, Bundy GL et al. Stereochemistry, total synthesis, and biological activity of 14, 15-dihydroxy-5, 8, 10, 12-eicosatetraenoic acid. J Biol Chem 1984;259:13011-6.
29. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 1983;220:568-75.
30. Nakamura M, Shimizu T. Leukotriene receptors. Chem Rev 2011;111:6231-98.
31. Pergola C, Werz O. 5-Lipoxygenase inhibitors: a review of recent developments and patents. Expert Opin Ther Pat 2010;20:355-75.
32. Hofmann B, Steinhilber D. 5-Lipoxygenase inhibitors: a review of recent patents (2010-2012). Expert Opin Ther Pat 2013;23:895-909.
33. Sorkness CA. The use of 5-lipoxygenase inhibitors and leukotriene receptor antagonists in the treatment of chronic asthma. Pharmacotherapy 1997;17:50S-4S.
34. Fischer AR, McFadden CA, Frantz R, Awni WM, Cohn J, Drazen JM et al. Effect of chronic 5-lipoxygenase inhibition on airway hyperresponsiveness in asthmatic subjects. Am J Respir Crit Care Med 1995;152:1203-7.
35. Capdevila J, Chacos N, Werringloer J, Prough RA, Estabrook RW. Liver microsomal cytochrome P-450 and the oxidative metabolism of arachidonic acid. Proc Natl Acad Sci USA 1981;78:5362-6.
36. Imig JD, Hammock BD. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov 2009;8:794-805.
37. Sisignano M, Park C-K, Angioni C, Zhang DD, von Hehn C, Cobos EJ et al. 5, 6-EET is released upon neuronal activity and induces mechanical pain hypersensitivity via TRPA1 on central afferent terminals. J Neurosci Off J Soc Neurosci 2012;32:6364-72.
38. Imig JD. Epoxides and soluble epoxide hydrolase in cardiovascular physiology. Physiol Rev 2012;92:101-30.
39. Shen HC. Soluble epoxide hydrolase inhibitors: a patent review. Expert Opin Ther Pat 2010;20:941-56.
40. Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999;285:1276-9.
41. He C, Wu Y, Lai Y, Cai Z, Liu Y, Lai L. Dynamic eicosanoid responses upon different inhibitor and combination treatments on the arachidonic acid metabolic network. Mol BioSyst 2012;8:1585-94.
42. Morphy R, Rankovic Z. Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem 2005;48:6523-43.
43. Lötsch J, Geisslinger G. Low-dose drug combinations along molecular pathways could maximize therapeutic effectiveness while minimizing collateral adverse effects. Drug Discov Today 2011;16:1001-6.
44. Morphy R, Kay C, Rankovic Z. From magic bullets to designed multiple ligands. Drug Discov Today 2004;9:641-51.
45. Kitano H. Computational systems biology. Nature 2002;420:206-10.
46. Hood L. Systems biology: integrating technology, biology, and computation. Mech Ageing Dev 2003;124:9-16.
47. Koeberle A, Rossi A, Bauer J, Dehm F, Verotta L, Northoff H et al. Hyperforin, an Anti-Inflammatory Constituent from St John's Wort, Inhibits Microsomal Prostaglandin E(2) Synthase-1 and Suppresses Prostaglandin E(2) Formation in vivo. Front Pharmacol 2011;2:7.
48. Abdel-Tawab M, Werz O, Schubert-Zsilavecz M. Boswellia serrata: an overall assessment of in vitro, preclinical, pharmacokinetic and clinical data. Clin Pharmacokinet 2011;50:349-69.
49. Poeckel D, Werz O. Boswellic acids: biological actions and molecular targets. Curr Med Chem 2006;13:3359-69.
50. Siemoneit U, Koeberle A, Rossi A, Dehm F, Verhoff M, Reckel S et al. Inhibition of microsomal prostaglandin E2 synthase-1 as a molecular basis for the anti-inflammatory actions of boswellic acids from frankincense. Br J Pharmacol 2011;162:147-62.
51. Tausch L, Henkel A, Siemoneit U, Poeckel D, Kather N, Franke L et al. Identification of human cathepsin G as a functional target of boswellic acids from the anti-inflammatory remedy frankincense. J Immunol Baltim Md 1950 2009;183:3433-42.
52. Maier TJ, Tausch L, Hoernig M, Coste O, Schmidt R, Angioni C et al. Celecoxib inhibits 5-lipoxygenase. Biochem Pharmacol 2008;76:862-72.
53. Steinbrink SD, Pergola C, Bühring U, George S, Metzner J, Fischer AS et al. Sulindac sulfide suppresses 5-lipoxygenase at clinically relevant concentrations. Cell Mol Life Sci 2010;67:797-806.
54. Rossi A, Pergola C, Koeberle A, Hoffmann M, Dehm F, Bramanti P et al. The 5-lipoxygenase inhibitor, zileuton, suppresses prostaglandin biosynthesis by inhibition of arachidonic acid release in macrophages. Br J Pharmacol 2010;161:555-70.
55. Schlosburg JE, Kinsey SG, Lichtman AH. Targeting fatty acid amide hydrolase (FAAH) to treat pain and inflammation. AAPS J 2009;11:39-44.
56. Forster L, Ludwig J, Kaptur M, Bovens S, Elfringhoff AS, Holtfrerich A et al. 1-Indol-1-yl-propan-2-ones and related heterocyclic compounds as dual inhibitors of cytosolic phospholipase A(2)alpha and fatty acid amide hydrolase. Bioorg Med Chem 2010;18:945-52.
57. Zahov S, Drews A, Hess M, Schulze Elfringhoff A, Lehr M. 1-(3-biaryloxy-2-oxopropyl)indole-5-carboxylic acids and related compounds as dual inhibitors of human cytosolic phospholipase A2α and fatty acid amide hydrolase. ChemMedChem 2011;6:544-9.
58. Wei D, Jiang X, Zhou L, Chen J, Chen Z, He C et al. Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching. J Med Chem 2008;51:7882-8.
59. Leone S, Ottani A, Bertolini A. Dual acting anti-inflammatory drugs. Curr Top Med Chem 2007;7:265-75.
60. Inagaki M, Tsuri T, Jyoyama H, Ono T, Yamada K, Kobayashi M et al. Novel antiarthritic agents with 1, 2-isothiazolidine-1, 1-dioxide (gamma-sultam) skeleton: cytokine suppressive dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase. J Med Chem 2000;43:2040-8.
61. Barbey S, Goossens L, Taverne T, Cornet J, Choesmel V, Rouaud C et al. Synthesis and activity of a new methoxytetrahydropyran derivative as dual cyclooxygenase-2/5-lipoxygenase inhibitor. Bioorg Med Chem Lett 2002;12:779-82.
62. Kulkarni SK, Singh VP. Licofelone-a novel analgesic and anti-inflammatory agent. Curr Top Med Chem 2007;7:251-63.
63. Fischer L, Hornig M, Pergola C, Meindl N, Franke L, Tanrikulu Y et al. The molecular mechanism of the inhibition by licofelone of the biosynthesis of 5-lipoxygenase products. Br J Pharmacol 2007;152:471-80.
64. Koeberle A, Siemoneit U, Bühring U, Northoff H, Laufer S, Albrecht W et al. Licofelone suppresses prostaglandin E2 formation by interference with the inducible microsomal prostaglandin E2 synthase-1. J Pharmacol Exp Ther 2008;326:975-82.
65. Liu J-Y, Yang J, Inceoglu B, Qiu H, Ulu A, Hwang S-H et al. Inhibition of soluble epoxide hydrolase enhances the anti-inflammatory effects of aspirin and 5-lipoxygenase activation protein inhibitor in a murine model. Biochem Pharmacol 2010;79:880-7.
66. Schmelzer KR, Kubala L, Newman JW, Kim I-H, Eiserich JP, Hammock BD. Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc Natl Acad Sci USA 2005;102:9772-7.
67. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S et al. Synthesis and Biological Evaluation of the 1, 5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors: Identification of 4-[5-(4-Methylphenyl)-3- (trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib). J Med Chem 1997;40:1347-65.
68. Hwang SH, Wagner KM, Morisseau C, Liu J-Y, Dong H, Wecksler AT et al. Synthesis and structure-activity relationship studies of urea-containing pyrazoles as dual inhibitors of cyclooxygenase-2 and soluble epoxide hydrolase. J Med Chem 2011;54:3037-50.
69. Jung O, Jansen F, Mieth A, Barbosa-Sicard E, Pliquett RU, Babelova A et al. Inhibition of the soluble epoxide hydrolase promotes albuminuria in mice with progressive renal disease. PLoS ONE 2010;5:e11979.
70. Meirer K, Rödl CB, Wisniewska JM, George S, Häfner A-K, Buscató El et al. Synthesis and structure-activity relationship studies of novel dual inhibitors of soluble epoxide hydrolase and 5-lipoxygenase. J Med Chem 2013;56:1777-81.
71. Wisniewska JM, Rödl CB, Kahnt AS, la Buscató E, Ulrich S, Tanrikulu Y et al. Molecular characterization of EP6-a novel imidazo[1, 2-a]pyridine based direct 5-lipoxygenase inhibitor. Biochem Pharmacol 2012;83:228-40.
72. Moser D, Wisniewska JM, Hahn S, Achenbach J, Buscató E, Klingler F-M et al. Dual-target virtual screening by pharmacophore elucidation and molecular shape filtering. ACS Med Chem Lett 2012;3:155-8.
73. Chen Z, Wu Y, Liu Y, Yang S, Chen Y, Lai L. Discovery of dual target inhibitors against cyclooxygenases and leukotriene A4 hydrolyase. J Med Chem 2011;54:3650-60.
74. Koeberle A, Zettl H, Greiner C, Wurglics M, Schubert-Zsilavecz M, Werz O. Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase. J Med Chem 2008;51:8068-76.
75. Wiegard A, Hanekamp W, Griessbach K, Fabian J, Lehr M. Pyrrole alkanoic acid derivatives as nuisance inhibitors of microsomal prostaglandin E2 synthase-1. Eur J Med Chem 2012;48:153-63.
76. Koeberle A, Rossi A, Zettl H, Pergola C, Dehm F, Bauer J et al. The molecular pharmacology and in vivo activity of 2-(4-chloro-6-(2, 3-dimethylphenylamino)pyrimidin-2-ylthio)octanoic acid (YS121), a dual inhibitor of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase. J Pharmacol Exp Ther 2010;332:840-8.
77. Hieke M, Greiner C, Thieme TM, Schubert-Zsilavecz M, Werz O, Zettl H. A novel class of dual mPGES-1/5-LO inhibitors based on the α-naphthyl pirinixic acid scaffold. Bioorg Med Chem Lett 2011;21:1329-33.
78. Elkady M, Nieß R, Schaible AM, Bauer J, Luderer S, Ambrosi G et al. Modified acidic nonsteroidal anti-inflammatory drugs as dual inhibitors of mPGES-1 and 5-LOX. J Med Chem 2012;55:8958-62.
79. Hibi S, Okamoto Y, Tagami K, Numata H, Kobayashi N, Shinoda M et al. Novel dual inhibitors of 5-lipoxygenase and thromboxane A2 synthetase: synthesis and structure-activity relationships of 3-pyridylmethyl-substituted 2-amino-6-hydroxybenzothiazole derivatives. J Med Chem 1994;37:3062-70.
80. Hibi S, Okamoto Y, Tagami K, Numata H, Kobayashi N, Shinoda M et al. Structure-activity relationships of (E)-3-(1, 4-benzoquinonyl)-2-[(3-pyridyl)-alkyl]-2-propenoic acid derivatives that inhibit both 5-lipoxygenase and thromboxane A2 synthetase. J Med Chem 1996;39:3148-57.
81. Bertinaria M, Shaikh MAAG, Buccellati C, Cena C, Rolando B, Lazzarato L et al. Designing multitarget anti-inflammatory agents: chemical modulation of the lumiracoxib structure toward dual thromboxane antagonists-COX-2 inhibitors. ChemMedChem 2012;7:1647-60.
82. Arakida Y, Suwa K, Ohga K, Yokota M, Miyata K, Yamada T et al. In vitro pharmacologic profile of YM158, a new dual antagonist for LTD4 and TXA2 receptors. J Pharmacol Exp Ther 1998;287:633-9.
83. Arakida Y, Ohga K, Suwa K, Okada Y, Morio H, Yokota M et al. Effect of YM158, a dual lipid mediator antagonist, on immediate and late asthmatic responses, and on airway hyper-responsiveness in guinea pigs. Jpn J Pharmacol 2000;82:287-94.